A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 08 May 2020
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amgen; Celgene Corporation
- 20 Aug 2019 Status changed from active, no longer recruiting to completed.
- 10 Aug 2019 Results published in the Journal of the American Academy of Dermatology
- 25 Jun 2018 Planned End Date changed from 15 Nov 2019 to 5 Aug 2019.